medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2019, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2019; 35 (3)

Characterization of Hodgkin's lymphoma in the adults patients

Quintero SY, Teruel HA, Hernández PC, Concepción FY, Romero GA, Macia PI

Language: Spanish
References: 48
Page: 1-39
PDF size: 760.61 Kb.


ABSTRACT

Introduction: Hodgkin's lymphoma has evolved to be one of the cancers with highest possibilities of cure. Objective: To characterize the behavior of the Hodgkin’s lymphoma disease in adult patients. Methods: An observational, descriptive and retrospective study was carried out. It included 75 adult patients with Hodgkin's lymphoma attended in the Institute of Hematology and Immunology since January 1987 to January of 2017. Results: 64 % of the patients were male; the white color of skin and the group from 18 to 38 years predominated, with 85.3 % and 68 % respectively. Patients without comorbidity prevailed, and those who had a good status performance, representing the 65.3 % and 93.3 % respectively. The 52 % of patients were in stage III at diagnosis, the group with advanced favorable disease was predominant, with 61.3 % of the cases. The most frequent histological type was nodular sclerosis with 48 patients; and ABVD protocol was used more often, achieving 92 % of complete remission. Twenty percent of the patients died and 18.7 % relapsed. The overall survival of the patients at 2, 5 and 10 years was 93 %, 83 % and 80 % respectively. The progression-free survival at of 5 and 10 years was 82 % and 73 % respectively. Conclusions: The overall survival and the progression-free survival of patients were high, and patients treated with the combination of chemotherapy and radiotherapy showed a significantly better overall survival.


REFERENCES

  1. Ministerio de Salud Pública. Linfoma Hodgkin en adultos: Guía Práctica Clínica (GPC). Quito: Dirección Nacional de Normalización;2017.

  2. Ron Guerrero CS, Ron Magaña AL, Medina Palacios CL, López Flores F. Epidemiología de los linfomas. del Centro Estatal de Cancerología de Nayarit. Rev Hematol Mex. 2015;16(2):109-14.

  3. Lara Torres C, Ortiz Hidalgo C. Diagnóstico histopatológico e inmunohistoquímico del linfoma de Hodgkin y su diagnóstico diferencial. Patología. 2009;47(1): 35-45.

  4. Press LW, Lichtman MA. General considerations for lymphomas: epidemiology, etiology, heterogeneity, and primary extranodal disease. En: Kaushansky K, Marshall LA, Prchal JT, Levi MM, Press OW, Burns LJ, et al. eds. Williams Hematology. 9a ed. New York: McGraw-Hill;2016. p.1569-83.

  5. Bellas Menéndez C. Linfoma Hodgkin. Rev Esp Patol. 2004;37(2):129-38.

  6. Eichenauer DA, Engert A, André M, Federico M, Illidge T, Hutchings M, et al. ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25(Suppl3):iii70-5. DOI: 10.1093/annonc/mdu181.

  7. Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea. Guía de práctica clínica para el tratamiento de pacientes con Linfoma de Hodgkin. Barcelona: Elsevier;2014. p.56.

  8. Rueda Domínguez A, Alfaro Lizaso J, de la Cruz M, Guma Padro J, Quero Blanco C, Gómez Codina J, et. al. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Clin Transl Oncol. 2015;(17):100513. DOI: 10.1007/s12094-015-1429-1.

  9. Alegría Valdivia ER, Grados Doroteo J, Rodríguez Hurtado D. Características clínicas de los linfomas no Hodgkin en el Hospital Nacional Arzobispo Loayza. Rev Soc Peru Med Interna. 2014;25 (1): 26-30.

  10. Linendoll N, Saunders T, Burns R, Nyce JD, Wendell KB, Evens KB, et. al. Health-related quality of life in Hodgkin lymphoma: a systematic review. Health and Quality of Life Outcomes. 2016;(14):114. DOI:10.1186/s12955-016-0515-6.

  11. Ansell SM. Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clin Proc. 2015 Nov;90(11):1574-83. DOI: 10.1016/j.mayocp.2015.07.005.

  12. American Cancer Society. Cancer Facts& Figures 2016. [Internet]. Atlanta: American Cancer Society;2016. [citado 01/11/2018] Disponible en: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdf

  13. Sociedad Argentina de Hematología. Guías de diagnóstico y tratamiento. Linfomas. Buenos Aires: SAH;2017.

  14. Ministerio de Salud Pública. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Mortalidad por cáncer en Cuba, 2016. En: Anuario Estadístico de Salud, 2016. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Salud;2017. [citado 01/11/2018]. Disponible en: http://files.sld.cu/dne/files/2017/05/Anuario_Estad%C3%ADstico_de_Salud_e_2016_edici%C3%B3n_2017.pdf

  15. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Incidencia por cáncer en Cuba, 2016. En: Anuario Estadístico de Salud, 2016. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Salud;2017. [citado 01/11/2018]. Disponible en: http://files.sld.cu/dne/files/2017/05/Anuario_Estad%C3%ADstico_de_Salud_e_2016_edici%C3%B3n_2017.pdf

  16. Wang Q, Qin Y, Kang SY, He XH, Liu P, Yang S, et al. Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era. Chin Med J (Engl). 2016 Dec;129(23):2780-5. DOI: 10.4103/0366-6999.194661.

  17. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008 Dec;112(12):4384-99. DOI: 10.1182/blood-2008-07-077982.

  18. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May;127(20):2375-90. DOI: 10.1182/blood-2016-01-643569.

  19. Delgado Vargas T, Carnot Uria J, de Castro Arenas R, Muñío Perurena J, Hernández Cruz C, Núñez Quintana A, et al. Causas de mortalidad en pacientes con linfoma de Hodgkin. Rev Cubana Med. 2015;54(2):231-41.

  20. Eichenauer DA, Engert A, Diehl V. Hodgkin lymphoma: clinical manifestations, staging, and therapy. In: Hoffman R, Benz EJ, Leslie E, Silberstein LE, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia: Elsevier Saunder;2013. p.1138-56.

  21. Peñarrubia Ponce MJ. Linfoma de Hodgkin. An Real Acad Med Cir Vall.2013;50:259-71.

  22. Villasboas JC, Ansell SM. Recent advances in the management of Hodgkin lymphoma. F1000Res. 2016;5: F1000 Faculty Rev-768. DOI: 10.12688/f1000research.8301.1

  23. Sánchez de Toledo Codina J, Sábado Álvarez C. Linfomas de Hodgkin y no Hodgkin. Pediatr Integral.2016;XX (6):390-400.

  24. Dann EJ. Hodgkin disease-an ever-evolving therapy. Rambam Maimonides Med J. 2014 Oct 29;5(4):e0029. DOI: 10.5041/RMMJ.10163.

  25. Fedele R, Martino M, Recchia AG, Irrera G, Gentile M, Morabito F. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. J Immunol Res. 2015;2015:968212. DOI: 10.1155/2015/968212.

  26. Sureda A. Factores pronósticos y tratamiento de primera línea del linfoma de Hodgkin. Haematologica.2014;95(extra 1):43-9.

  27. Press OW. Hodgkin Lymphoma. En: Kaushansky K, Marshall LA, Prchal JT, et al, (editors). Williams Hematology. 9na ed. New York: McGraw-Hill;2016. p.1603-19.

  28. Palacios D, García CF, Andrade R, García A. Enfermedad de Hodgkin Análisis de 309 casos diagnosticados en la Fundación Santa Fe de Bogotá. Acta Médica Colombiana.2011;22(6) 42-56.

  29. Salati M, Cesaretti M, Macchia M, Mistiri ME, Federico M. Epidemiological Overview of Hodgkin Lymphoma across the Mediterranean Basin. Mediterr J Hematol Infect Dis. 2014 Jul;6(1):e2014048. DOI: 10.4084/MJHID.2014.048.

  30. Rugbjerg K, Maraldo M, Aznar MC, Cutter DJ, Darby SC, Specht L, et al. Long-term hospital isation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nation wide cohort study. Int J Cancer. 2017 May;140(10):2232-45. DOI: 10.1002/ijc.30655.

  31. Díaz J, Soto K, Ernst D. Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado. Rev Med Chile.2017;145(5):619-622.

  32. Linendoll N, Saunders T, Burns R, Nyce JD, Wendell KB, Evens KB, et. al. Health-related quality of life in Hodgkin lymphoma: a systematic review. Health and Quality of Life Outcomes. 2016;(14):114. DOI:10.1186/s12955-016-0515-6.

  33. Magyari F, Kósa K, Berecz R, Illés A, Miltényi Z, Simon Z, et al. Á. Employment status and health related quality of life among Hodgkin-lymphoma survivors'- results based on data from a major treatment center in Hungary. Health Qual Life Outcomes. 2017 Sep;15(1):180. DOI: 10.1186/s12955-017-0758-x.

  34. Covarrubias Espinoza G, Luna Cordova JA, Rendón García H, Gómez Maqueo Chew A, Morales Peralta, Larios Farak T, et al. Linfoma de Hodgkin. Factores Pronósticos Asociados a la Respuesta del Tratamiento. Bol Clin Hosp Infant Edo Son. 2016;33(1):90-5.

  35. Alonso Mariño OL, Alonso Mariño AL, Miranda Chaviano J. Caracterización clínico-epidemiológica de los linfomas en un período de cinco años en Villa Clara. Medicentro Electrónica.2015;19(1):13-20.

  36. Karantanos T, Politikos I, Boussiotis VA. Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with a emphasis on targeted therapies and transplantation strategies. Blood Lymphat Cancer. 2017;(7):37–52. DOI: 10.2147/BLCTT.S105458.

  37. Siddiqi T, Thomas SH, Chen R. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Pharm genomics Pers Med. 2014 Feb;7:79-85. DOI: 10.2147/PGPM.S57700.

  38. Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016 Jun;91(4):434-42. DOI: 10.1002/ajh.24272.

  39. Eichenauer DJ, Becker I, Monsef K, Chadwick N, Sanctis V, Fortpied C, et al. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica. 2017 Oct;102(10):1748-57. DOI: 10.3324/haematol.2017.167478.

  40. Hoppe RT, Advani RH, Weiyun ZA, Ambinder RF, Aoun P, Bello MC, et al. Hodgkin Lymphoma, Version 2.2015:ClinicalPracticeGuidelines in Oncology. J Natl Compr Canc Netw 2018;16(3):245–54. DOI: 10.6004/jnccn.2018.0013

  41. Ali S, Basit A, Kazmi AS, Sidhu A, Badar F, Hameed A. Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience. Pak J Med Sci. 2016 Nov-Dec;32(6):1408-13. DOI: 10.12669/pjms.326.11080.

  42. Massumoto C, Tabacof J, Alencar A, Scheinberg P. linfoma de Hodgkin. En: Scheinberg P, Alencar A.eds. Manual de Oncología Clínica de Brasil. Hematología y Trasplante. 2a ed. Sao Paulo: Dendrix;2013. p.109-19.

  43. Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov;27(32):5390-6. DOI: 10.1200/JCO.2009.23.3239.

  44. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA non bulky Hodgkin disease. Blood.2014 Dec;104(12): 3483-9.

  45. Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, et al;European Organization for Research and Treatment of Cancer Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2013 Jun;348(24):2396-406.

  46. Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010 Jul;28(20):3352-9. DOI: 10.1200/JCO.2009.26.0323.

  47. Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. BJC. 2015;112:1575–84. DOI: 10.1038/bjc.2015.94.

  48. Ye X, Mahmud S, Skrabek P, Lix L, Johnston JB. Long-term time trends in incidence, survival and mortality of lymphomas by subtype among adults in Manitoba, Canada: a population-based study using cancer registry data. BMJ Open. 2017;7:e015106. DOI:10.1136/bmjopen-2016-015106.




2020     |     www.medigraphic.com